|
| U.S. Brand
Names |
|
| Coly-Mycin® S
Oral |

|
|
| Generic
Available |
|
|
No |

|
|
| Synonyms |
|
|
Colistin Sulfate; Polymyxin E |

|
|
| Pharmacological Index |
|
|
Antibiotic, Miscellaneous; Antidiarrheal |

|
|
| Use |
|
|
Treatment of diarrhea in infants and children caused by susceptible
organisms, especially E. coli and Shigella, however, other
agents are preferred; treatment of superficial infections of external ear canal
and of mastoidectomy and fenestration cavities |

|
|
| Pregnancy Risk
Factor |
|
|
C |

|
|
| Contraindications |
|
|
Known hypersensitivity to colistin |

|
|
| Warnings/Precautions |
|
|
Use with caution in patients with impaired renal function; some systemic
absorption may occur; potential for renal toxicity exists; prolonged use may
lead to superinfection |

|
|
| Adverse
Reactions |
|
|
<1%: Neuromuscular blockade, nephrotoxicity, respiratory arrest, nausea,
vomiting, hypersensitivity reactions, superinfections |

|
|
| Stability |
|
|
Stable for 2 weeks when refrigerated, shake well; discard after 14
days |

|
|
| Mechanism of
Action |
|
|
Polypeptide antibiotic that binds to and damages the bacterial cell
membrane |

|
|
| Pharmacodynamics/Kinetics |
|
|
Absorption: Oral: Slightly absorbed from GI tract (adults); unpredictable
absorption occurs in infants, can lead to significant serum levels
Half-life: 2.8-4.8 hours, prolonged in renal insufficiency; with anuria:
48-72 hours
Elimination: ~65% to 75% excreted unchanged in urine |

|
|
| Usual Dosage |
|
|
Diarrhea: Children: Oral: 5-15 mg/kg/day in 3 divided doses given every 8
hours |

|
|
| Mental Health: Effects
on Mental Status |
|
|
None reported |

|
|
| Mental Health:
Effects on Psychiatric
Treatment |
|
|
None reported |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
Keep refrigerated, shake well, discard after 14 days |

|
|
| Dosage Forms |
|
|
Powder for oral suspension: 25 mg/5 mL (60
mL) |

|
|
Copyright © 2007 Drugs Area
|